The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
Abstract
BACKGROUND Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-to-severe atopic dermatitis, a common immunoinflammatory skin disease. This study assessed the efficacy and safety of abrocitinib versus dupilumab. METHODS This randomised, double-blind, double-dummy, active-controlled, parallel-treatment, phase 3 trial enrolled adults with moderate-to-severe atopic dermatitis who requir=ed systemic therapy or had inadequate response to topical medications. Participants were enrolled from 151 sites, located in Australia, Bulgaria, Canada, Chile, Finland, Germany, Hungary, Italy, Latvia, Poland, Slovakia, South Korea, Spain, Taiwan, and the USA. These participants were then randomly assigned (1:1) with block randomisation to receive oral abrocitinib (200 mg per day) or subcutaneous dupilumab (300 mg every 2 weeks) for 26 weeks. Participants were required to apply topical corticosteroids (medium or low potency), topical calcineurin inhibitors, or a topical phosphodiesterase 4 inhibitor to active lesion areas. Primary endpoints were response based on achieving a 4 point or higher improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) at week 2 and a 90% or better improvement in Eczema Area and Severity Index (EASI-90) at week 4. Family-wise type 1 error was controlled via a sequential multiple-testing procedure (two sided, α=0·05). Randomly assigned participants who received at least one dose of study intervention were included in the efficacy and safety analysis sets. This trial was completed on July 13, 2021 (NCT04345367). FINDINGS Between June 11, 2020, and Dec 16, 2020, 940 patients were screened and 727 were enrolled (362 in the abrocitinib group and 365 in the dupilumab group). Compared with dupilumab, a larger proportion of patients treated with abrocitinib reached the primary outcomes, PP-NRS4 at week 2 (172 [48%] of 357, 95% CI 43·0-53·4 vs 93 [26%] of 364, 21·1-30·0; difference 22·6%, 15·8-29·5; p<0·0001), and EASI-90 at week 4 (101 [29%] of 354, 23·8-33·2 vs 53 [15%] of 364, 10·9-18·2; difference 14·1%, 8·2-20·0; p<0·0001). Treatment-emergent adverse events were reported by 268 (74%) of 362 patients treated with abrocitinib and by 239 (65%) of 365 patients treated with dupilumab. Two non-treatment-related deaths occurred in the abrocitinib group. INTERPRETATION Abrocitinib 200 mg per day was more efficacious than dupilumab in adults with moderate-to-severe atopic dermatitis on background topical therapy in inducing early reductions of itch and atopic dermatitis disease signs. Both treatments were well tolerated over 26 weeks. FUNDING Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3023 · Cited by 516
Self-citation
Cited by
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P.-Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1110765 · Cited by 339
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
Guttman-Yassky, E., Renert-Yuval, Y., & Brunner, P. M. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02519-4 · Cited by 321
Davis, D. M. R., Drucker, A. M., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.08.102 · Cited by 265
Recent advancements in the atopic dermatitis mechanism
Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902084 · Cited by 53
“Abrocitinib is a safe and effective therapeutic agent, currently approved for adults and adolescents in the USA and UK with moderate to severe AD, while approval for 12 to 18-year-old AD patients is currently awaited in Europe [22–24].”
Background
Metadata
- Authors
- Reich, K., Thyssen, J. P., Blauvelt, A., Eyerich, K., Soong, W., Rice, Z. P., Hong, H. C.-H., Katoh, N., Valenzuela, F., DiBonaventura, M., Bratt, T. A., Zhang, F., Clibborn, C., Rojo, R., Valdez, H., & Kerkmann, U.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 400
- Issue
- 10348
- Pages
- 273-282
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4286515998
- Cited by
- 251
- References
- 2
- FWCI
- 39.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01199-0
- The paper
- Reich, K., Thyssen, J. P., Blauvelt, A., Eyerich, K., Soong, W., Rice, Z. P., Hong, H. C.-H., Katoh, N., Valenzuela, F., DiBonaventura, M., Bratt, T. A., Zhang, F., Clibborn, C., Rojo, R., Valdez, H., & Kerkmann, U. (2022). Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)01199-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.